SMS Pharmaceuticals Limited Receives Non‐Exclusive License To Manufacture And Supply Of Nirmatrelvir (An Oral COVID‐ 19 Medicine) Through The Medicine Patent Pool
![](https://healthwire.co/wp-content/uploads/2022/01/Drug-price.jpg)
SMS Pharmaceuticals Limited has received a non‐exclusive license through the Medicines Patent Pool (MPP) to manufacture nirmatrelvir, an oral antiviral COVID‐19 medicine developed by Pfizer, to increase broad access to…
Share